/
/
Clinical Trial: Daratumumab with Revlimid, Velcade and dex for Newly Diagnosed Myeloma
Clinical Trial: Daratumumab with Revlimid, Velcade and dex for Newly Diagnosed Myeloma image
Clinical Trial: Daratumumab with Revlimid, Velcade and dex for Newly Diagnosed Myeloma
Posted Dec 22, 2017

Revlimid, Velcade and dexamethasone (also called RVd) are considered to be an optimal treatment for newly diagnosed myeloma. The combination can be used as "induction" therapy prior to transplant or can be used for transplant-ineligible patients. Daratumumab has been added to this effective regimen for relapsed or refractory myeloma patients with successful results. Now researchers want to know if it can be moved up in the therapy line for newly diagnosed patients. Because there are such strong responses, they want to know if using daratumumab in earlier settings could be beneficial to delay the disease from returning and help patients live longer overall. Dr. Larry Anderson of the UT Southwestern Medical Center shares more about this open clinical trial in the video below. To learn more about joining this clinical trial that is open at 45 centers, you can find it on SparkCures here: Dara with RVd Clinical Trial    

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811